Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the clinical activity of SNS-032.
Tumors
DRUG: SNS-032 Injection
Safety|Tolerability
Pharmacokinetic profile|Effect on QT interval|Potential biomarkers|Anti-tumor activity
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the body), preliminary evaluation of biomarkers to see how the levels of certain proteins change after administration of SNS-032; assessment of the effects of SNS-032 on QT interval.